Trending News Today: Lilly Cancer Drug Fails to Improve Survival in Clinical Trial

 Eli Lilly’s cancer treatment Lartruvo, which received accelerated FDA approval in 2016, failed to improve patient survival in a key study, Reuters reported. According to the article, Lartruvo combined with the standard-of-care chemotherapy doxorubicin did not prolong survival more than doxorubicin alone in patients with advanced soft tissue sarcoma. No new US patients will be started on the drug and Lilly is suspending promotion of the medicine, the article reported.
FDA Commissioner Scott Gottlieb, MD, said in a public hearing on Friday that the level of young individuals addicted to e-cigarettes may warrant potential drug therapies, The Hill reported. According to the article, Dr Gottlieb said that levels of e-cigarette use among minors are increasing while traditional cigarette use drops to historic lows. Currently, the number of middle and high school students who regularly use e-cigarettes is 3.6 million, which increased by approximately 1.5 million from the previous year, the article noted.
The number of opioid prescriptions in Hawaii has declined over the last 4 years, which has been credited in part to the Hawaii Prescription Drug Monitoring Program, the Associated Press reported. According to the article, state Department of Health epidemiologist Dr Daniel Galanis said the database has drastically reduced the number of patients who obtain prescriptions. The average number of monthly opioid prescriptions decreased from approximately 69,000 in 2015 to 54,500 last year, the article reported.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

Study recommends similar clinical thresholds for diagnosing and managing giant cell arteritis for patients of different ethnicities.
The approval of fedratinib (Inrebic, Celgene) provides another treatment option for patients with myelofibrosis, a rare bone marrow disorder.
Top news of the day from across the health care landscape.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.